Monopar Therapeutics Files 8-K for Regulation FD Disclosure
Ticker: MNPR · Form: 8-K · Filed: Feb 20, 2024 · CIK: 1645469
| Field | Detail |
|---|---|
| Company | Monopar Therapeutics (MNPR) |
| Form Type | 8-K |
| Filed Date | Feb 20, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulation-fd, disclosure
TL;DR
**Monopar Therapeutics just filed an 8-K for Regulation FD Disclosure, meaning they've released new public info.**
AI Summary
Monopar Therapeutics Inc. filed an 8-K on February 20, 2024, under accession number 0001437749-24-004724. The filing indicates a Regulation FD Disclosure and includes Financial Statements and Exhibits. The company, incorporated in Delaware with IRS number 32-0463781, is headquartered at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091.
Why It Matters
This filing provides transparency regarding information Monopar Therapeutics Inc. has disclosed to the public, ensuring fair and equal access to material information for all investors.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure filing and does not inherently indicate significant financial or operational risk.
Key Numbers
- 2024-02-20 — Date of Report (Earliest event reported)
- 001-39070 — SEC File Number (Monopar Therapeutics' SEC filing identifier)
- 32-0463781 — IRS Employer Identification No. (Monopar Therapeutics' tax identifier)
- 847-388-0349 — Business Phone (Monopar Therapeutics' contact number)
- 17 — Public Document Count (Number of documents in the filing)
Key Players & Entities
- Monopar Therapeutics Inc. (company) — Registrant
- Delaware (company) — State of incorporation
- 001-39070 (dollar_amount) — Commission File Number
- 32-0463781 (dollar_amount) — I.R.S. Employer Identification No.
- 1000 Skokie Blvd. , Suite 350 , Wilmette , IL 60091 (company) — Address of principal executive offices
FAQ
What is the accession number for this 8-K filing?
The accession number for this 8-K filing is 0001437749-24-004724.
What is the date of the earliest event reported in this 8-K?
The date of the earliest event reported in this 8-K is February 20, 2024.
What items are disclosed in this 8-K filing?
This 8-K filing includes Item Information regarding Regulation FD Disclosure and Financial Statements and Exhibits.
Where is Monopar Therapeutics Inc. headquartered?
Monopar Therapeutics Inc. is headquartered at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091.
What is Monopar Therapeutics Inc.'s SEC File Number?
Monopar Therapeutics Inc.'s SEC File Number is 001-39070.
Filing Stats: 443 words · 2 min read · ~1 pages · Grade level 10.4 · Accepted 2024-02-20 08:00:15
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value MNPR The Nasdaq Stock Mar
Filing Documents
- mnpr20240216_8k.htm (8-K) — 25KB
- ex_627936.htm (EX-99.1) — 10KB
- monologo.jpg (GRAPHIC) — 4KB
- 0001437749-24-004724.txt ( ) — 179KB
- mnpr-20240220.xsd (EX-101.SCH) — 3KB
- mnpr-20240220_def.xml (EX-101.DEF) — 12KB
- mnpr-20240220_lab.xml (EX-101.LAB) — 16KB
- mnpr-20240220_pre.xml (EX-101.PRE) — 12KB
- mnpr20240216_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On February 20, 2024, Monopar Therapeutics Inc. issued a press release announcing it has received Human Research Ethics Committee (HREC) clearance in Australia to commence a Phase 1 dosimetry trial of its novel radiopharmaceutical MNPR-101-Zr. The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release Dated February 20, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Monopar Therapeutics Inc. Date: February 20, 2024 By: /s/ Kim R. Tsuchimoto Name: Kim R. Tsuchimoto Title: Chief Financial Officer and Director